FHTX
Foghorn Therapeutics Inc.
$6.00
+0.95 (+18.81%)
At close · Jul 7
Market Cap
$352.28M
Shares
58,713,922
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.00
Open$5.05
Day$5.05–6.24
52W$3.27–6.95
Avg vol 30d266K
Short int1.4M · 2.4% float · 8.6d
Short vol38%
Last earningsMay 7, 2026
DataOct 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+24% above
+
Price vs 50-day avg
+38% above
−
RSI (14)
78 · overbought
+
MACD trend
positive
◦
52-week position
74% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $4 › 200d $5 — 200d above 50d
−
Institutional flow
1 of 104 funds reported for Jun 30 · net -229 sh shares
◦
Insider flow
No net insider activity over 90 days
+
Short interest
2.38% of float · ▼ -5.3% MoM · 8.6 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
104 holders — near 3-yr high, broad support
Fundamentals
Strong
+
Revenue growth
+37% Y/Y
+
EPS growth
+25% Y/Y
−
Free cash flow
$-86.1M
+
Balance sheet
net cash $61.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 3, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+24% above
Bullish
Price vs 50-day avg
+38% above
Bullish
RSI (14)
78 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
74% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Distributing
1 of 104 funds reported for Jun 30 · net -229 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.38% of float · ▼ -5.3% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
104 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $6 · 74%
52-wk high $7
vs 200-day avg +24%
vs 50-day avg +38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FHTX
this stock
Foghorn Therapeutics Inc.
|
$352.28M | +11.1% | +36.8% | — | 2.4% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FHTX | +23.5% | +60.9% | -6.0% | +23.0% | +11.1% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +22.6% | +59.5% | -13.5% | +22.8% | +1.5% |